Mizuho raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $29 from $24 and keeps a Neutral rating on the shares. The firm upped the company’s sales estimates post the “solid” Q4 report, driven by higher Nuplazid expectations. However, it sees a balanced risk/reward at current share levels.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals price target lowered to $31 from $33 at JPMorgan
- ACADIA Pharmaceuticals: Strong Financial Performance and Strategic Growth Initiatives Drive Buy Rating
- ACADIA Pharmaceuticals Q3 2025 Earnings Call Highlights
- ACADIA Pharmaceuticals: Strong Growth Prospects and Strategic Positioning Justify Buy Rating
- ACADIA Pharmaceuticals: Hold Rating Amid Stable U.S. Performance and Growth Potential